Publications and Papers

Publications and Papers2025-03-27T10:51:19+11:00

MIA researchers play a significant role in expanding world knowledge about melanoma. We’ve compiled a list of all recent publications so you can access all MIA research papers in one place.

Erratum: First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data.

2025-04-07T12:08:39+10:00March 7th, 2025|

Long GV, Lipson EJ, Hodi FS, Ascierto PA, Larkin J, Lao C, Grob J-J, Ejzykowicz F, Moshyk A, Garcia-Horton V, Zhou Z-Y, Xin Y, Palaia J, McDonald L, Keidel S, Salvatore A, Patel D, Sakkal LA, Tawbi H, Schadendorf D. Journal of Clinical Oncology, 0, no. 0, (Mar 07 2025): JCO-25-00452, doi:10.1200/jco-25-00452. TOP 10%

|

Association of inherited genetic variants with multiple primary melanoma.

2025-04-07T11:57:25+10:00March 4th, 2025|

Gibbs DC, Small BM, Autuori I, Leong SF, Ali E, Kenney J, Luo L, Kanetsky PA, Busam KJ, Cust AE, Anton-Culver H, Gallagher RP, Zanetti R, Rosso S, Sacchetto L, Edmiston SN, Conway K, Ollila DW, Begg CB, Berwick M, Orlow I, Thomas NE. Cancer Epidemiol Biomarkers Prev, (Mar 4 2025), doi:10.1158/1055-9965.Epi-24-1442.

|

Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study.

2025-03-27T15:26:42+11:00March 3rd, 2025|

Nassar AH, Abou Alaiwi S, El Zarif T, Denu R, Macaron W, Abdel-Wahab N, Freeman D, Vasbinder A, Hayeck S, Anderson E, Goodman RS, Johnson DB, Grynberg S, Shapira R, Kwan JM, Woodford R, Long GV, Haykal T, Dent S, Kojima Y, Yonemor K, Tandon A, Trevino A, Akhter N, Yang EH, Hui G, Drakaki A, El-Am E, Kozaily E, Al-Hader A, Bou Farhat E, Babu P, Mittra A, Li M, Jones N, Baena J, Juarez Herrera M, Foderaro S, Nana FA, Kim C, Sackstein P, Parikh K, Desai AP, Smith C, Cortellini A, Pinato DJ, Korolewicz J, Lopetegui-Lia N, Funchain P, Choudhary A, Asnani A, Navani V, Meyers D, Stukalin I, Ocejo Gallegos JA, Trent J, Nusrat S, Malvar C, McKay RR, Neilan TG, Choueiri TK, Naqash AR. J Immunother Cancer, 13, no. 3, (Mar 3 2025), doi:10.1136/jitc-2024-009364.

|

Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma.

2025-03-27T14:52:54+11:00February 27th, 2025|

Long GV, Shklovskaya E, Satgunaseelan L, Mao Y, da Silva IP, Perry KA, Diefenbach RJ, Gide TN, Shivalingam B, Buckland ME, Gonzalez M, Caixeiro N, Vergara IA, Bai X, Rawson RV, Hsiao E, Palendira U, Phan TG, Menzies AM, Carlino MS, Quek C, Grimmond SM, Vissers JHA, Yeo D, Rasko JEJ, Khasraw M, Neyns B, Reardon DA, Ashley DM, Wheeler H, Back M, Scolyer RA, Drummond J, Wilmott JS, Rizos H. Nature Medicine, (Feb 27 2025), doi:10.1038/s41591-025-03512-1. TOP 1%

|

Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell Carcinoma.

2025-03-27T15:17:13+11:00February 25th, 2025|

Mo J, Zaremba A, Inderjeeth A-J, El Zeinaty P, Li A, Wicky A, Della Marta N, Marqueste CG, Bohne A-S, Matias M, McNamee N, Festino L, Chen C, Ch’ng S, van Akkooi ACJ, Meda LD, Park JJ, Ascierto PA, Hauschild A, Lee JH, Grob JJ, Mangana J, Guminski A, Michielin O, Xu W, Lebbe C, Sandhu S, Zimmer L, Menzies AM, Lo SN, Long GV, Carlino MS, da Silva IP. European Journal of Cancer, 217(Feb 25 2025), doi:10.1016/j.ejca.2025.115254.

|

Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

2025-03-27T13:56:32+11:00February 7th, 2025|

Kennedy OJ, Glassee N, Kicinski M, Bührer E, Valpione S, Gandini S, Suciu S, Blank CU, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Boers-Sonderen M, Di Giacomo AM, van den Eertwegh AJM, Grob J-J, Gutzmer R, Jamal R, van Akkooi ACJ, Robert C, Eggermont AMM, Lorigan P, Mandala M. EJC Skin Cancer, (Feb 07 2025): 100284, doi:https://doi.org/10.1016/j.ejcskn.2025.100284.

|

Response to han and liu.

2025-03-27T14:16:10+11:00February 6th, 2025|

Lo SN, Varey AHR, Ch’ng S, Scolyer RA, Thompson JF. J Natl Cancer Inst, (Feb 6 2025), doi:10.1093/jnci/djaf026. TOP 10%

|

Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance.

2025-04-07T12:33:21+10:00February 6th, 2025|

Newell F, Pires da Silva I, Johansson PA, Menzies AM, Wilmott JS, Addala V, Carlino MS, Rizos H, Nones K, Edwards JJ, Lakis V, Kazakoff SH, Mukhopadhyay P, Ferguson PM, Leonard C, Koufariotis LT, Wood S, Blank CU, Thompson JF, Spillane AJ, Saw RPM, Shannon KF, Pearson JV, Mann GJ, Hayward NK, Scolyer RA, Waddell N, Long GV. Cancer Cell, (Feb 06 2025), doi:https://doi.org/10.1016/j.ccell.2025.01.011. TOP 10%

|

Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma.

2025-03-27T15:21:31+11:00February 3rd, 2025|

Munoz-Couselo E, Soria Rivas A, Sandhu S, Long GV, Sanmamed MF, Spreafico A, Buchbinder E, Sznol M, Prenen H, Fedenko A, Milhem M, Arance Fernandez AM, Grob JJ, Demidov L, Robert C, Habigt C, Evers S, Sleiman N, Dejardin D, Ardeshir C, Martin N, Boetsch C, Charo J, Teichgraeber V, Kraxner A, Keshelava N, Bechter O. Cancer Res Commun, (Feb 3 2025), doi:10.1158/2767-9764.Crc-24-0601.

|

Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial.

2025-03-31T15:51:39+11:00February 1st, 2025|

Yoon CH, Ross MI, Gastman BR, Luke JJ, Ascierto PA, Long GV, Rutkowski P, Khattak M, Del Vecchio M, de la Cruz Merino L, Mackiewicz J, Chiarion-Sileni V, Schadendorf D, Carlino MS, Zhao Y, Fukunaga-Kalabis M, Krepler C, Eggermont Alexander MM, Gershenwald JE, Sondak VK. Annals of Surgical Oncology, (Feb 01 2025), doi:10.1245/s10434-024-16642-6.

|

European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics – Update 2024.

2025-03-27T12:29:38+11:00January 17th, 2025|

Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, Bastholt L, Bataille V, Brochez L, Del Marmol V, Dréno B, Eggermont AMM, Fargnoli MC, Forsea AM, Höller C, Kaufmann R, Kelleners-Smeets N, Lallas A, Lebbé C, Leiter U, Longo C, Malvehy J, Moreno-Ramirez D, Nathan P, Pellacani G, Saiag P, Stockfleth E, Stratigos AJ, Van Akkooi ACJ, Vieira R, Zalaudek I, Lorigan P, Mandala M. Eur J Cancer, 215(Jan 17 2025): 115152, doi:10.1016/j.ejca.2024.115152.

|

Cancer cells impair monocyte-mediated T cell stimulation to evade immunity.

2025-04-07T11:50:44+10:00January 16th, 2025|

Elewaut A, Estivill G, Bayerl F, Castillon L, Novatchkova M, Pottendorfer E, Hoffmann-Haas L, Schönlein M, Nguyen TV, Lauss M, Andreatta F, Vulin M, Krecioch I, Bayerl J, Pedde A-M, Fabre N, Holstein F, Cronin SM, Rieser S, Laniti DD, Barras D, Coukos G, Quek C, Bai X, Muñoz i Ordoño M, Wiesner T, Zuber J, Jönsson G, Böttcher JP, Vanharanta S, Obenauf AC. Nature, 637, no. 8046, (Jan 16 2025): 716-25, doi:10.1038/s41586-024-08257-4. TOP 1%

|

Sex differences in melanoma survival-a GEM study.

2025-04-07T12:28:40+10:00January 3rd, 2025|

Murali T, Schwartz M, Reynolds AZ, Luo L, Ridgeway G, Busam KJ, Cust AE, Anton-Culver H, Gallagher RP, Zanetti R, Rosso S, Sacchetto L, Begg CB, Orlow I, Thomas NE, Berwick M. JNCI Cancer Spectr, 9, no. 1, (Jan 3 2025), doi:10.1093/jncics/pkaf005.

|

Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey.

2025-03-27T13:42:04+11:00January 1st, 2025|

Hauschild A, Garbe C, Ascierto PA, Demidov L, Dreno B, Dummer R, Eggermont A, Forsea A-M, Gebhardt C, Gershenwald JE, Hamid O, Hoeller C, Kandolf L, Kaufmann R, Kirkwood JM, Lebbé C, Long GV, Malvehy J, Martin-Algarra S, McArthur G, Neyns B, Richtig E, Robert C, Schadendorf D, Scolyer R, Sondak VK, Wainstein A, Weichenthal M, Nuti P, Aarts MJB, Arance A, Asher N, Berciano-Guerrero M-A, Berking C, Carlino MS, Dabelić N, Davar D, Espinosa E, Forschner A, Gaide O, Gaudy-Marqueste C, Gavrilova I, Grabbe S, Gutzmer R, Hafner C, Hassel JC, Jacobs C, Jang S, Kähler KC, Kehrer H, Koelblinger P, Leiter U, Lipson EJ, Livingstone E, Luke JJ, Mandalà M, Mangana J, Marić Brozić J, Marquez-Rodas I, Maul LV, Mazilu L, Mehmi I, Meier F, Mesti T, Mitchell TC, Mohr P, Moyers J, Muñoz Couselo E, Najjar YG, Nakamura Y, Ocvirk J, Orlova K, Popescu BC, Popovic A, Posch C, Queirolo P, Ramelyte E, Roberts-Thomson R, Rorive A, Ruhlmann CH, Rutten A, Salama AKS, Samoylenko I, Schilling B, Shalamanova-Deleva G, Siano M, Smithy JW, Stelzhammer P, Suijkerbuijk K, Terheyden P, Teterycz P, Tietze JK, Urbonas V, Utyashev I, van der Veldt AAM, Venter M, Zarour HM, Zimmer L, Zinovev G. The Lancet Oncology, 26, no. 1, (Jan 2025): 12-14, doi:10.1016/S1470-2045(24)00627-2. TOP 10%

|

Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors.

2025-03-27T11:57:51+11:00January 1st, 2025|

Dimitriou F, Orloff MM, Koch Hein EC, Cheng PF, Hughes IF, Simeone E, Montazeri K, Grover P, Mehmi I, Gerard CL, Gaudy-Marqueste C, Grob J-J, Michielin O, Hamid O, Long GV, Sullivan R, Kapiteijn E, Johnson DB, Ascierto PA, Joshua AM, Carvajal RD, Butler MO, Hassel JC, Dummer R. European Journal of Cancer, 214(Jan 01 2025): 115161, doi:https://doi.org/10.1016/j.ejca.2024.115161.

|

Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined With Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies.

2025-04-07T12:12:37+10:00December 13th, 2024|

Luke JJ, Gelmon K, Siu LL, Moreno V, Desai J, Gomez-Roca CA, Carlino MS, Pachynski RK, Cosman R, Chu QS, Damian S, Curigliano G, Tam R, Wang X, Jeyamohan C, Wang L, Zhu L, Santucci-Pereira J, Greenawalt DM, Tabernero J. Clin Cancer Res, (Dec 13 2024), doi:10.1158/1078-0432.Ccr-24-0439. TOP 10%

|

Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma.

2025-03-27T13:34:07+11:00December 8th, 2024|

Handel EE, McKeown J, Wei J, Kankaria RA, Burnette H, Johnson DB, Lawless A, Czapla J, Sullivan RJ, Albrecht LJ, Zimmer L, Mangana J, Dummer R, Kessels JI, Neyns B, Allayous C, Lebbe C, Boatwright C, Mehnert JM, Ottaviano M, Ascierto PA, Czarnecka AM, Rutkowski P, Lo SN, Long GV, Menzies AM, Carlino MS. European Journal of Cancer, (Dec 08 2024), doi:10.1016/j.ejca.2024.115171.

|

Nivolumab (NIVO) plus relatlimab (RELA) vs. NIVO in previously untreated, metastatic, or unresectable melanoma (RELATIVITY-047): 3- year overall survival (OS) and melanoma-specific survival (MSS) results.

2025-04-03T10:22:00+11:00December 1st, 2024|

Tawbi HA, Hodi S, Lipson EJ, Schadendorf D, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance AM, Grob JJ, Ratto B, Rodriguez S, Mazzei A, Dolfi S, Long G. Annals of Dermatology and Venereology – FMC, 4, no. 8, Supplement 1, (Dec 01 2024): A349-A50, doi:https://doi.org/10.1016/j.fander.2024.09.415.

|

121MO Anti-IL-8 (BMS-986253) in combination with nivolumab (NIVO) plus ipilimumab (IPI) in patients (pts) with advanced melanoma: Final analysis from the randomized part 2 of the phase I/II CA027-002 study.

2025-04-03T10:15:46+11:00December 1st, 2024|

Simonelli M, Butler MO, Ascierto PA, Long GV, Calvo E, Garcia VM, Gebhardt C, Grob JJ, Haydon AM, Quereux G, Walker J, Kumar M, Chakraborty D, Zhu X, Melero I. Immuno-Oncology and Technology, 24(Dec 2024), https://doi.org/10.1016/j.iotech.2024.100750.

|

Efficacy and safety of nivolumab + relatlimab (NIVO+RELA) versus nivolumab + ipilimuab (NIVO+IPI) in the first-line (1L) treatment of advanced melanoma: updated data from an indirect treatment comparison.

2025-04-03T10:08:56+11:00December 1st, 2024|

Schadendorf D, Tawbi HA, Lipson EJ, Hodi S, Ascierto PA, Larkin J, Lao CD, Grob JJ, Ejzykowicz F, Palaia J, Garcia-Horton V, Zhou ZY, Christensen D, Rosenblatt L, McDonald L, Ratto B, Salvatore A, Patel D, Sakkal LA, Dalle S, Long G. Annals of Dermatology and Venereology – FMC, 4, no. 8, Supplement 1, (Dec 01 2024): A82-A83, doi:https://doi.org/10.1016/j.fander.2024.09.510.

|

Nivolumab vs. Placebo in the Adjuvant Treatment of Patients with Stage IIB/C Melanoma: 3-Year Results of the CheckMate 76K (CM 76K) Study.

2025-04-03T09:51:44+11:00December 1st, 2024|

Long G, Del Vecchio M, Hoeller C, Weber J, Grob JJ, Morh P, Grabbe S, Dutriaux C, Chiarion-Sileni V, Mackiewicz J, Rutkowski P, Arenberger P, Quéreux G, Meniawy T, Ascierto PA, Taube J, Nassar A, Wang W, Kirkwood JM. Annals of Dermatology and Venereology – FMC, 4, no. 8, Supplement 1, (Dec 01 2024): A94-A95, doi:https://doi.org/10.1016/j.fander.2024.09.527.

|

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2024.

2025-03-27T13:21:02+11:00November 29th, 2024|

Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, Bastholt L, Bataille V, Brochez L, del Marmol V, Dréno B, Eggermont AMM, Fargnoli MC, Forsea A-M, Höller C, Kaufmann R, Kelleners-Smeets N, Lallas A, Lebbé C, Leiter U, Longo C, Malvehy J, Moreno-Ramirez D, Nathan P, Pellacani G, Saiag P, Stockfleth E, Stratigos AJ, Van Akkooi ACJ, Vieira R, Zalaudek I, Lorigan P, Mandala M. European Journal of Cancer, (Nov 29 2024): 115153, doi:https://doi.org/10.1016/j.ejca.2024.115153.

|

Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo.

2025-03-27T16:27:55+11:00November 19th, 2024|

Reijers ILM, Menzies AM, Lopez-Yurda M, Versluis JM, Rozeman EA, Saw RPM, van Houdt WJ, Kapiteijn E, van der Veldt AAM, Suijkerbuijk KPM, Eriksson H, Hospers GAP, Mc Klop W, Acosta AT, Grijpink-Ongering L, Gonzalez M, van der Wal A, Al-Mamgani A, Spillane AJ, Scolyer RA, van de Wiel BA, van Akkooi ACJ, Long GV, Blank CU. European Journal of Cancer, (Nov 19 2024): 115141, doi:https://doi.org/10.1016/j.ejca.2024.115141.

|

Long-term Outcomes among Patients Who Respond within the First Year to Nivolumab plus Ipilimumab or Nivolumab Monotherapy: A Pooled Analysis in 935 Patients.

2025-03-27T16:35:31+11:00November 16th, 2024|

Robert C, Long GV, Larkin J, Wolchok JD, Hassel JC, Schadendorf D, Hodi FS, Lebbé C, Grob JJ, Hyngstrom JR, Wagstaff J, Chesney J, Butler MO, Bechter O, Márquez-Rodas I, Pavlick AC, Durani P, Pe Benito M, Wang P, Postow MA, Ascierto PA. European Journal of Cancer, (Nov 16 2024): 115119, doi:https://doi.org/10.1016/j.ejca.2024.115119.

|

Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

2025-03-27T10:47:19+11:00November 14th, 2024|

Amaral T, Ottaviano M, Arance A, Blank C, Chiarion-Sileni V, Donia M, Dummer R, Garbe C, Gershenwald JE, Gogas H, Guckenberger M, Haanen J, Hamid O, Hauschild A, Höller C, Lebbé C, Lee RJ, Long GV, Lorigan P, Couselo EM, Nathan P, Robert C, Romano E, Schadendorf D, Sondak V, Suijkerbuijk KPM, van Akkooi ACJ, Michelin O, Ascierto PA. Annals of Oncology, (Nov 14 2024), doi:10.1016/j.annonc.2024.11.006. TOP 10%

|

A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastases

2025-03-27T11:48:52+11:00November 10th, 2024|

DePalo DK, Dugan MM, Naqvi SMH, Ollila DW, Hieken TJ, Block MS, van Houdt WJ, Wouters M, Reijers SJM, Asher N, Broman KK, Duncan Z, Anderson M, Gyorki DE, Snow H, Held J, Farma JM, Vetto JT, Hui JYC, Kolbow M, Saw RPM, Lo SN, Long GV, Thompson JF, Kim Y, Karapetyan L, Ny L, van Akkooi ACJ, Bagge RO, Zager JS. Cancer, (Nov 10 2024), doi:10.1002/cncr.35636.

|

DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance.

2025-03-27T11:22:38+11:00November 8th, 2024|

Conway K, Edmiston SN, Vondras A, Reiner A, Corcoran DL, Shen R, Parrish EA, Hao H, Lin L, Kenney JM, Ilelaboye G, Kostrzewa CE, Kuan PF, Busam KJ, Lezcano C, Lee TK, Hernando E, Googe PB, Ollila DW, Moschos S, Gorlov I, Amos CI, Ernstoff MS, Cust AE, Wilmott JS, Scolyer RA, Mann GJ, Vergara IA, Ko J, Rees JR, Yan S, Nagore E, Bosenberg M, Rothberg BG, Osman I, Lee JE, Saenger Y, Bogner P, Thompson CL, Gerstenblith M, Holmen SL, Funchain P, Brunsgaard E, Depcik-Smith ND, Luo L, Boyce T, Orlow I, Begg CB, Berwick M, Thomas NE. JCO Precis Oncol, 8(Nov 2024): e2400375, doi:10.1200/po-24-00375.

|

Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma.

2025-03-27T14:47:50+11:00November 6th, 2024|

Long GV, Larkin J, Schadendorf D, Grob J-J, Lao CD, Márquez-Rodas I, Wagstaff J, Lebbé C, Pigozzo J, Robert C, Ascierto PA, Atkinson V, Postow MA, Atkins MB, Sznol M, Callahan MK, Topalian SL, Sosman JA, Kotapati S, Thakkar PK, Ritchings C, Benito MP, Re S, Soleymani S, Hodi FS. Journal of Clinical Oncology, (Nov 06 2024): JCO.24.00400, doi:10.1200/jco.24.00400. TOP 10%

|

Acceptability and timing considerations when administering patient-reported outcome measures (PROMs) among people with chronic health conditions who are culturally and linguistically diverse (CALD): a qualitative study protocol.

2025-03-27T15:35:45+11:00September 12th, 2024|

Nikolovski J, Morton RL, Mercieca-Bebber R, Armstrong M, Hartas G, Rossiter B, Fagan M, Tinsley M, Snyder C, Aiyegbusi OL, Amin-Korim R, Sutherland K, Rutherford C. BMJ Open, 14, no. 9, (Sep 12 2024): e083346, doi:10.1136/bmjopen-2023-083346.

|

The effect of a single dose of nivolumab prior to isolated limb perfusion for patients with in-transit melanoma metastases: An interim analysis of a phase Ib/II randomized double-blind placebo-controlled trial (NivoILP trial).

2025-04-03T12:19:53+11:00June 1st, 2024|

Holmberg C-J, Zijlker LP, Katsarelias D, Huibers AE, Wouters MWJM, Schrage Y, Reijers SJM, van Thienen JV, Grünhagen DJ, Martner A, Nilsson JA, van Akkooi ACJ, Ny L, van Houdt WJ, Bagge RO. European Journal of Surgical Oncology, 50, no. 6, (Jun 2024): 108265, doi:https://doi.org/10.1016/j.ejso.2024.108265.

|

Neoadjuvant Triplet Immune Checkpoint Blockade in Newly Diagnosed Glioblastoma.

2025-04-03T14:58:02+11:00April 28th, 2024|

Long G, Wilmott J, Shklovskaya E, Satgunseelan L, Mao Y, Perry K, Diefenbach R, Gide T, Shivalingam B, Buckland ME, Gonzalez M, Caixeiro NJ, Vergara I, Bai X, Hsiao E, Rawson R, da Silva I, Palendira U, Phan T, Menzies A, Carlino M, Quek C, Grimmond SM, Vissers J, Yeo D, Rasko JE, Khasraw M, Neytns B, Reardon D, Ashley DM, Wheeler H, Back M, Drummond J, Scolyer R, Rizos H. Nature Portfolio, (Preprint Apr 28 2024), doi:https://doi.org/10.21203/rs.3.rs-4255559/v1.

|

Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease.

2025-04-03T15:11:52+11:00April 18th, 2024|

Luke JJ, Davar D, Andtbacka RH, Bhardwaj N, Brody JD, Chesney J, Coffin R, de Baere T, de Gruijl TD, Fury M, Goldmacher G, Harrington KJ, Kaufman H, Kelly CM, Khilnani AD, Liu K, Loi S, Long GV, Melero I, Middleton M, Neyns B, Pinato DJ, Sheth RA, Solomon SB, Szapary P, Marabelle A. J Immunother Cancer, 12, no. 4, (Apr 18 2024), doi:10.1136/jitc-2023-008378.

|

The Impact of Next-generation Sequencing on Interobserver Agreement and Diagnostic Accuracy of Desmoplastic Melanocytic Neoplasms

2024-06-13T16:07:01+10:00April 9th, 2024|

Chen A, Sharma N, Patel P, Olivares S, Bahrami A, Barnhill RL, Blokx WAM, Bosenberg M, Busam KJ, de La Fouchardière A, Duncan LM, Elder DE, Ko JS, Landman G, Lazar AJ, Lezcano C, Lowe L, Maher N, Massi D, Messina J, Mihic-Probst D, Parker DC, Redpath M, Scolyer RA, Shea CR, Spatz A, Tron V, Xu X, Yeh I, Jung Yun S, Zembowicz A, Gerami P. Am J Surg Pathol, doi:10.1097/pas.0000000000002226.

|

Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis.

2025-04-03T15:56:03+11:00April 1st, 2024|

Stassen RC, Maas CCHM, van der Veldt AAM, Lo SN, Saw RPM, Varey AHR, Scolyer RA, Long GV, Thompson JF, Rutkowski P, Keilholz U, van Akkooi ACJ, Verhoef C, van Klaveren D, Grünhagen DJ. The Lancet Oncology, 25, no. 4, (Apr 01 2024): 509-17, doi:10.1016/S1470-2045(24)00076-7. TOP 10%

|

BRAF Mutated and Morphologically Spitzoid Tumors, a Subgroup of Melanocytic Neoplasms Difficult to Distinguish From True Spitz Neoplasms.

2025-04-03T12:00:03+11:00March 25th, 2024|

Gerami P, Chen A, Sharma N, Patel P, Hagstrom M, Kancherla P, Geraminejad T, Olivares S, Biswas A, Bosenberg M, Busam KJ, de La Fouchardière A, Duncan LM, Elder DE, Ko J, Landman G, Lazar AJ, Lowe L, Massi D, Mihic-Probst D, Parker DC, Scolyer RA, Shea CR, Zembowicz A, Yun SJ, Blokx WAM, Barnhill RL. Am J Surg Pathol, (Mar 25 2024), doi:10.1097/pas.0000000000002194. TOP 10%

|

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial.

2024-05-09T12:13:11+10:00March 13th, 2024|

Schadendorf D, Luke JJ, Ascierto PA, Long GV, Rutkowski P, Khattak M, Del Vecchio M, de la Cruz Merino L, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob J-J, Dummer R, Carlino MS, Zhao Y, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Scolyer RA. Journal of Immunotherapy of Cancer.

|

Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study.

2025-04-03T15:06:45+11:00March 7th, 2024|

Luke JJ, Ascierto PA, Khattak MA, Merino LdlC, Vecchio MD, Rutkowski P, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob J-J, Galitiis Fd, Schadendorf D, Carlino MS, Wu XL, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Long GV. Journal of Clinical Oncology, 0, no. 0, (Mar 07 2024): JCO.23.02355, doi:10.1200/jco.23.02355. TOP 10%

|

Technical considerations for isolated limb perfusion: A consensus paper.

2025-04-03T12:08:25+11:00March 6th, 2024|

Hayes AJ, Coker DJ, Been L, Boecxstaens VW, Bonvalot S, De Cian F, de la Cruz-Merino L, Duarte C, Eggermont A, Farricha V, Fiore M, Grünhagen D, Grützmann R, Honoré C, Jakob J, Hocevar M, van Houdt W, Klauzner J, Kettelhack C, Märten A, Martinez-Said H, Matter M, Michot A, Niethard M, Pennacchioli E, Podleska LE, Rabago G, Rastrelli M, Reijers S, Ribeiro M, Schwarzbach M, Snow HA, Spacek M, Stoldt S, Testori A, Zoras O, Olofsson Bagge R. Eur J Surg Oncol, 50, no. 6, (Mar 6 2024): 108050, doi:10.1016/j.ejso.2024.108050.

|

Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma

2024-06-03T15:46:56+10:00March 1st, 2024|

Albrecht LJ, Dimitriou F, Grover P, Hassel JC, Erdmann M, Forschner A, Johnson DB, Váraljai R, Lodde G, Placke JM, Krefting F, Zaremba A, Ugurel S, Roesch A, Schulz C, Berking C, Pöttgen C, Menzies AM, Long GV, Dummer R, Livingstone E, Schadendorf D, Zimmer L. European Journal of Cancer, doi:10.1016/j.ejca.2024.113976.

|

Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy.

2025-04-03T12:31:28+11:00March 1st, 2024|

Jacques SK, McKeown J, Grover P, Johnson DB, Zaremba A, Dimitriou F, Weiser R, Farid M, Namikawa K, Sullivan RJ, Rutkowski P, Lebbe C, Hamid O, Zager JS, Michielin O, Neyns B, Nakamura Y, Robert C, Mehnert J, Ascierto PA, Bhave P, Park B, Zimmer L, Mangana J, Mooradian M, Placzke J, Allayous C, Glitza Oliva IC, Mehmi I, Depalo D, Wicky A, Schwarze JK, Roy S, Boatwright C, Vanella V, Long GV, Menzies AM, Lo SN, Carlino MS. Eur J Cancer, 199(Mar 2024): 113563, doi:10.1016/j.ejca.2024.113563.

|

Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.

2025-04-03T16:32:40+11:00February 17th, 2024|

Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, Kim KB, McKean M, Long GV, Sullivan RJ, Faries M, Tran TT, Cowey CL, Pecora A, Shaheen M, Segar J, Medina T, Atkinson V, Gibney GT, Luke JJ, Thomas S, Buchbinder EI, Healy JA, Huang M, Morrissey M, Feldman I, Sehgal V, Robert-Tissot C, Hou P, Zhu L, Brown M, Aanur P, Meehan RS, Zaks T. Lancet, 403, no. 10427, (Feb 17 2024): 632-44, doi:10.1016/s0140-6736(23)02268-7. TOP 1%

|

Health Economic Consequences Associated With COVID-19-Related Delay in Melanoma Diagnosis in Europe.

2025-04-03T15:16:08+11:00February 5th, 2024|

Maul LV, Jamiolkowski D, Lapides RA, Mueller AM, Hauschild A, Garbe C, Lorigan P, Gershenwald JE, Ascierto PA, Long GV, Wang-Evers M, Scolyer RA, Saravi B, Augustin M, Navarini AA, Legge S, Németh IB, Jánosi Á J, Mocellin S, Feller A, Manstein D, Zink A, Maul JT, Buja A, Adhikari K, Roider E. JAMA Netw Open, 7, no. 2, (Feb 5 2024): e2356479, doi:10.1001/jamanetworkopen.2023.56479. TOP 10%

|

Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

2025-04-03T12:50:35+11:00February 1st, 2024|

Kennedy OJ, Glassee N, Kicinski M, Blank CU, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Boers-Sonderen M, Giacomo AMD, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Gandini S, Buhrer E, Suciu S, Robert C, Eggermont AMM, Mandala M, Lorigan P, Valpione S. Eur J Cancer, 201(Feb 1 2024): 113585, doi:10.1016/j.ejca.2024.113585.

|

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention-Update 2023.

2025-04-24T14:51:04+10:00July 28th, 2023|

Stratigos AJ, Garbe C, Dessinioti C, Lebbe C, van Akkooi A, Bataille V, Bastholt L, Dreno B, Dummer R, Fargnoli MC, Forsea AM, Harwood CA, Hauschild A, Hoeller C, Kandolf-Sekulovic L, Kaufmann R, Kelleners-Smeets NWJ, Lallas A, Leiter U, Malvehy J, del Marmol V, Moreno-Ramirez D, Pellacani G, Peris K, Saiag P, Tagliaferri L, Trakatelli M, Ioannides D, Vieira R, Zalaudek I, Arenberger P, Eggermont AMM, Rocken M, Grob J-J, Lorigan P. European Journal of Cancer, (Jul 28 2023), doi:10.1016/j.ejca.2023.113251.

|

Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy).

2025-04-24T12:41:18+10:00July 28th, 2023|

Ascierto PA, Agarwala SS, Warner AB, Ernstoff MS, Fox BA, Gajewski TF, Galon J, Garbe C, Gastman BR, Gershenwald JE, Kalinski P, Krogsgaard M, Leidner RS, Lo RS, Menzies AM, Michielin O, Poulikakos PI, Weber JS, Caracò C, Osman I, Puzanov I, Thurin M. Journal of Translational Medicine, 21, no. 1, (Jul 28 2023): 508, doi:10.1186/s12967-023-04325-x.

|

Looking beyond workforce parity: addressing gender inequity in pathology.

2025-04-24T14:19:46+10:00July 25th, 2023|

McKenzie CA, Gupta R, Jackett L, Anderson L, Chen V, Dahlstrom JE, Dray M, Farshid G, Hemmings C, Karim R, Kench JG, Klebe S, Kramer N, Kumarasinghe P, Maclean F, Morey A, Nguyen MA, O’Toole S, Rowbotham B, Salisbury ELC, Scolyer RA, Stewart K, Waring L, Cooper CL, Cooper WA. Pathology, (Jul 25 2023), doi:https://doi.org/10.1016/j.pathol.2023.07.002.

|

Cutaneous melanoma

2023-08-16T11:29:16+10:00July 24th, 2023|

Georgina V Long, Susan M Swetter, Alexander M Menzies, Jeffrey E Gershenwald, Richard A Scolyer. Lancet 2023 Jul 24;S0140-6736(23)00821-8. doi: 10.1016/S0140-6736(23)00821-8.

|

Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia.

2025-04-24T12:59:04+10:00July 4th, 2023|

Cass SH, Tobin JWD, Seo YD, Gener-Ricos G, Keung EZ, Burton EM, Davies MA, McQuade JL, Lazar AJ, Mason R, Millward M, Sandhu S, Khoo C, Warburton L, Guerra V, Haydon A, Dearden H, Menzies AM, Carlino M, Smith JL, Mollee P, Burgess M, Mapp S, Keane C, Atkinson V, Parikh SA, Markovic SN, Ding W, Call TG, Hampel PJ, Long GV, Wargo JA, Ferrajoli A. Ann Oncol, (Jul 4 2023), doi:10.1016/j.annonc.2023.06.007. TOP 10%

|

Delphi Consensus Among International Experts on the Diagnosis, Management, and Surveillance for Lentigo Maligna.

2025-04-24T14:12:14+10:00July 1st, 2023|

Longo C, Navarrete-Dechent C, Tschandl P, Apalla Z, Argenziano G, Braun RP, Bataille V, Cabo H, Hoffmann-Wellhenhof R, Forsea AM, Garbe C, Guitera P, Raimond K, Marghoob AA, Malvehy J, Del Marmol V, Moreno D, Nehal KS, Nagore E, Paoli J, Pellacani G, Peris K, Puig S, Soyer HP, Swetter S, Stratigos A, Stolz W, Thomas L, Tiodorovic D, Zalaudek I, Kittler H, Lallas A. Dermatol Pract Concept, 13, no. 3, (Jul 1 2023), doi:10.5826/dpc.1303a244.

|

Neoadjuvant immunotherapy for melanoma is now ready for clinical practice.

2025-04-24T13:43:51+10:00May 16th, 2023|

Garbe C, Dummer R, Amaral T, Amaria RN, Ascierto PA, Burton EM, Dreno B, Eggermont AMM, Hauschild A, Hoeller C, Kaufmann R, Lebbe C, Mandala M, Menzies AM, Moreno D, Michielin O, Nathan P, Patel SP, Robert C, Schadendorf D, Lorigan PC, Scolyer RA, Tawbi HA, van de Wiel BA, Blank C, Long GV. Nature Medicine, (May 16 2023), doi:10.1038/s41591-023-02336-1. TOP 1%

|

Regarding: Predicting Regional Lymph Node Recurrence in The Modern Age of Tumor-Positive Sentinel Node Melanoma.

2025-04-24T14:54:48+10:00May 6th, 2023|

Thompson JF, Hyngstrom J, Caracò C, Zager JS, Jahkola T, Bowles TL, Pennacchioli E, Hoekstra HJ, Moncrieff M, Ingvar C, van Akkooi A, Sabel MS, Levine EA, Henderson M, Dummer R, Rossi CR, Kane JM, Trocha S, Wright F, Byrd DR, Matter M, MacKenzie-Ross A, Kelley MC, Terheyden P, Huston TL, Wayne JD, Neuman H, Smithers BM, Desai D, Gershenwald JE, Schneebaum S, Gesierich A, Jacobs LK, Lewis JM, O’Donoghue C, Sardi A, McKinnon JG, Slingluff CL, Farma JM, Schultz E, Scheri RP, Vidal-Sicart S, Testori AAE, Scolyer RA, Elashoff DE, Cochran AJ, Faries MB. Annals of Surgical Oncology, (May 06 2023), doi:10.1245/s10434-023-13570-9.

|

Study protocol for a randomised controlled trial to evaluate the use of melanoma surveillance photography to the Improve early detection of MelanomA in ultra-hiGh and high-risk patiEnts (the IMAGE trial).

2023-05-15T22:05:53+10:00March 29th, 2023|

Yan MK, Cust AE, Soyer HP, Janda M, Loewe K, Byars G, Fishburn P, White P, Mahumud RA, Saw RPM, Herschtal A, Fernandez-Penas P, Guitera P, Morton RL, Kelly J, Wolfe R, Mar VJ.  Trials. 2023 Mar 29;24(1):236. doi: 10.1186/s13063-023-07203-5. PMID: 36991460; PMCID: PMC10061902

|

REPLY to MS#JAAD-D-23-00002R1.

2023-05-15T20:05:54+10:00March 17th, 2023|

El Sharouni MA, Lo SN, Scolyer RA, van Gils CH, Thompson JF. J Am Acad Dermatol. 2023 Mar 17:S0190-9622(23)00440-1. doi: 10.1016/j.jaad.2023.03.008. Epub ahead of print. PMID: 36935017.

|

IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma.

2023-05-14T19:44:01+10:00March 15th, 2023|

Reijers ILM, Rao D, Versluis JM, Menzies AM, Dimitriadis P, Wouters MW, Spillane AJ, Klop WMC, Broeks A, Bosch LJW, Lopez-Yurda M, van Houdt WJ, Rawson RV, Grijpink-Ongering LG, Gonzalez M, Cornelissen S, Bouwman J, Sanders J, Plasmeijer E, Elshot YS, Scolyer RA, van de Wiel BA, Peeper DS, van Akkooi ACJ, Long GV, Blank CU. J Exp Med. 2023 May 1;220(5):e20221952. doi: 10.1084/jem.20221952. Epub 2023 Mar 15. PMID: 36920329; PMCID: PMC10037109.

|

MC1R ‘r’ allele does not increase melanoma risk in MITF E318K carriers.

2023-05-15T20:42:49+10:00March 5th, 2023|

Wallingford CK, Demeshko A, Krishnankutty Krishnakripa A, Smit DJ, Duffy DL, Betz-Stablein B, Pflugfelder A, Jagirdar K, Holland E, Mann GJ, Primiero CA, Yanes T, Malvehy J, Badenas C, Carrera C, Aguilera P, Olsen CM, Ward SV, Haass NK, Sturm RA, Puig S, Whiteman DC, Law MH, Cust AE, Potrony M, Soyer HP, McInerney-Leo AM. Br J Dermatol. 2023 Mar 5:ljad041. doi: 10.1093/bjd/ljad041. Epub ahead of print. PMID: 36879448.

|

Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients.

2023-05-14T17:39:43+10:00March 2nd, 2023|

Allen NC, Martin AJ, Snaidr VA, Eggins R, Chong AH, Fernandéz-Peñas P, Gin D, Sidhu S, Paddon VL, Banney LA, Lim A, Upjohn E, Schaider H, Ganhewa AD, Nguyen J, McKenzie CA, Prakash S, McLean C, Lochhead A, Ibbetson J, Dettrick A, Landgren A, Allnutt KJ, Allison C, Davenport RB, Mumford BP, Wong B, Stagg B, Tedman A, Gribbin H, Edwards HA, De Rosa N, Stewart T, Doolan BJ, Kok Y, Simpson K, Low ZM, Kovitwanichkanont T, Scolyer RA, Dhillon HM, Vardy JL, Chadban SJ, Bowen DG, Chen AC, Damian DL. N Engl J Med. 2023 Mar 2;388(9):804-812. doi: 10.1056/NEJMoa2203086. PMID: 36856616.

|

Clinical features and outcomes of cardiac involvement in patients with cancer treated with immune checkpoint inhibitors.

2023-05-14T19:23:51+10:00March 1st, 2023|
Sarah Abou Alaiwi, Amin Nassar, Talal Zarif, Edward El-Am, Ryan Denu, Walid Macaron, Carmel Malvar, Alessio Cortellini, James Korolewicz, Paul Sackstein, Frank Aboubakar Nana, Rachel Woodford, Georgina V. Long, Jennifer Kwan, Shirly Grynberg, Ronnie Shapira, Mercedes Herrera-Juárez, Simone Foderaro, Alexi Vasbinder, Aarti Asnani, Ankita Tandon, Salim Hayek, Tomas G. Neilan, Toni Choueiri, and Abdul-Rafeh Naqash.  J Am Coll Cardiol. 2023 Mar, 81 (8_Supplement) 2338.https://doi.org/10.1016/S0735-1097(23)02782-1
|

Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey.

2023-05-14T17:31:03+10:00February 24th, 2023|

Linardou H, Adjei AA, Bajpai J, Banerjee S, Berghoff AS, Mathias CC, Choo SP, Dent R, Felip E, Furness AJS, Garassino MC, Garralda E, Konsoulova-Kirova A, Letsch A, Menzies AM, Mukherji D, Peters S, Sessa C, Tsang J, Yang JC, Garrido P. ESMO Open. 2023 Feb 24;8(2):100781. doi: 10.1016/j.esmoop.2023.100781. Epub ahead of print. PMID: 36842299.

|

Reply to A. Mangla and E. Hindié.

2023-05-15T13:34:42+10:00February 20th, 2023|

Moncrieff MD, Sondak VK, Thompson JF, Zager JS.  J Clin Oncol. 2023 Feb 20;41(6):1326-1327. doi: 10.1200/JCO.22.02218. Epub 2022 Dec 1. PMID: 36455171.

|

Intratumoral CD16+ macrophages are associated with clinical outcomes of patients with metastatic melanoma treated with combination anti-PD-1 and anti-CTLA-4 therapy.

2023-05-15T20:22:46+10:00February 15th, 2023|

Lee H, Ferguson AL, Quek C, Vergara IA, Pires daSilva I, Allen R, Gide TN, Conway JW, Koufariotis LT, Hayward NK, Waddell N, Carlino MS, Menzies AM, Saw RPM, Shklovskaya E, Rizos H, Lo S, Scolyer RA, Long GV, Palendira U, Wilmott JS. Clin Cancer Res. 2023 Feb 15:CCR-22-2657. doi: 10.1158/1078-0432.CCR-22-2657. Epub ahead of print. PMID: 36790412.

|

Longitudinal trajectory of quality of life for patients with melanoma brain metastases: A secondary analysis from a whole brain radiotherapy randomized clinical trial.

2023-05-14T17:00:47+10:00February 15th, 2023|

Bartula I, Anh D. Tran, Anna K. Nowak, Tasnia Ahmed, Rachael L. Morton, Bryan H. Burmeister, Kari Dolven-Jacobsen, Jenny Nobes, John F. Thompson, Gerald B. Fogarty, Serigne N Lo, Angela M. Hong. Clinical and Translational Radiation Oncology,
2. 2023, 100597, ISSN 2405-6308, https://doi.org/10.1016/j.ctro.2023.100597

|

Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial

2023-05-14T16:06:01+10:00February 13th, 2023|

Ascierto PA, Lipson EJ, Dummer R, Larkin J, Long GV, Sanborn RE, Chiarion-Sileni V, Dréno B, Dalle S, Schadendorf D, Callahan MK, Nyakas M, Atkinson V, Gomez-Roca CA, Yamazaki N, Tawbi HA, Sarkis N, Warad D, Dolfi S, Mitra P, Suryawanshi S, Grob J-J.  Journal of Clinical Oncology, (Feb 13 2023): JCO.22.02072, doi:10.1200/jco.22.02072.

|

Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.

2023-05-15T21:32:50+10:00February 7th, 2023|

Boshuizen J, Vredevoogd DW, Krijgsman O, Ligtenberg MA, Blankenstein S, de Bruijn B, Frederick DT, Kenski JCN, Parren M, Brüggemann M, Madu MF, Rozeman EA, Song JY, Horlings HM, Blank CU, van Akkooi ACJ, Flaherty KT, Boland GM, Peeper DS.  Nat Commun. 2023 Feb 7;14(1):672. doi: 10.1038/s41467-023-35852-2. Erratum for: Nat Commun. 2020 Aug 7;11(1):3946. PMID: 36750559; PMCID: PMC9905532.

|

Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases.

2023-05-14T16:54:39+10:00February 1st, 2023|

Wilmott JS, Tawbi H, Engh JA, Amankulor NM, Shivalingam B, Banerjee H, Vergara IA, Lee H, Johansson PA, Ferguson PM, Saiag P, Robert C, Grob JJ, Butterfield LH, Scolyer RA, Kirkwood JM, Long GV, Davies MA. Clin Cancer Res, 29, no. 3, (Feb 1 2023): 521-31, doi:10.1158/1078-0432.Ccr-22-2581

|

IFNγ signaling sensitizes melanoma cells to BH3 Mimetics.

2023-05-14T16:40:18+10:00February 1st, 2023|

Ming Z, Lim SY, Stewart A, Pedersen B, Shklovskaya E, Menzies AM, Carlino MS, Kefford RF, Lee JH, Scolyer RA, Long GV, Rizos H.  Journal of Investigative Dermatology, (Feb 01 2023), doi:https://doi.org/10.1016/j.jid.2023.01.017.

|

ASO Visual Abstract: Is a History of Optimal Staging by SLNB in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

2023-05-15T21:52:04+10:00January 30th, 2023|

Blankenstein SA, Bonenkamp JJ, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Blokx WAM, Boers-Sonderen MJ, van den Eertwegh AJM, Franken MG, de Groot JWB, Haanen JBAG, Hospers GAP, Kapiteijn EW, van Not OJ, Piersma D, van Rijn RS, Suijkerbuijk KPM, van der Veldt AAM, Vreugdenhil G, Westgeest HM, Wouters MWJM, van Akkooi ACJ. Ann Surg Oncol. 2023 Jan;30(1):587-588. doi: 10.1245/s10434-022-12719-2. PMID: 36319872.

|

Association of Germline Variants in Telomere Maintenance Genes (POT1, TERF2IP, ACD, TERT) with Spitzoid Morphology in Familial Melanoma: A Multi-Center Case Series.

2023-05-14T16:36:38+10:00January 28th, 2023|

Goldstein AM, Qin R, Chu EY, Elder DE, Massi D, Adams DJ, Harms PW, Robles-Espinoza CD, Newton-Bishop JA, Bishop DT, Harland M, Holland EA, Cust AE, Schmid H, Mann GJ, Puig S, Potrony M, Alos L, Nagore E, Millán-Esteban D, Hayward NK, Broit N, Palmer JM, Nathan V, Berry EG, Astiazaran-Symonds E, Yang XR, Tucker MA, Landi MT, Pfeiffer RM, Sargen MR. JAAD International, (Jan 28 2023), doi:10.1016/j.jdin.2023.01.013.

|

Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials.

2023-05-14T16:01:42+10:00January 18th, 2023|

Versluis JM, Menzies AM, Sikorska K, Rozeman EA, Saw RPM, van Houdt WJ, Eriksson H, Klop WMC, Ch’ng S, van Thienen JV, Mallo H, Gonzalez M, Torres Acosta A, Grijpink-Ongering LG, van der Wal A, Bruining A, van de Wiel BA, Scolyer RA, Haanen J, Schumacher TN, van Akkooi ACJ, Long GV, Blank CU.  Ann Oncol, (Jan 18 2023), doi:10.1016/j.annonc.2023.01.004

|

Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.

2023-05-14T15:15:25+10:00January 10th, 2023|

Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JA.  Nature, (Jan 10 2023), doi:10.1038/s41586-022-05632-x.

 

|

Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma

2023-05-14T11:12:23+10:00January 9th, 2023|

Wong SK, Blum SM, Sun X, Pires Da Silva I, Zubiri L, Ye F, Bai K, Zhang K, Ugurel S, Zimmer L, Livingstone E, Schadendorf D, Serra-Bellver P, Muñoz-Couselo E, Ortiz C, Lostes J, Huertas RM, Arance A, Pickering L, Long GV, Carlino MS, Buchbinder EI, Vázquez-Cortés L, Jara-Casas D, Márquez-Rodas I, González-Espinoza IR, Balko JM, Menzies AM, Sullivan RJ, Johnson DB. European Journal of Cancer, 2022, ISSN 0959-8049

|

Revision of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis Classification Schema for Melanocytic Lesions: A Consensus Statement

2023-04-03T10:14:47+10:00January 3rd, 2023|

Barnhill RL, Elder DE, Piepkorn MW, Knezevich SR, Reisch LM, Eguchi MM, Bastian BC, Blokx W, Bosenberg M, Busam KJ, Carr R, Cochran A, Cook MG, Duncan LM, Elenitsas R, de la Fouchardière A, Gerami P, Johansson I, Ko J, Landman G, Lazar AJ, Lowe L, Massi D, Messina J, Mihic-Probst D, Parker DC, Schmidt B, Shea CR, Scolyer RA, Tetzlaff M, Xu X, Yeh I, Zembowicz A, Elmore JG.  JAMA Netw Open. 2023 Jan 3;6(1):e2250613. doi: 10.1001/jamanetworkopen.2022.50613. PMID: 36630138.

|

Embedding electronic patient-reported outcome measures into routine care for patients with stage III MELanoma (ePROMs-MEL): protocol for a prospective, longitudinal, mixed-methods pilot study.

2023-05-15T13:41:18+10:00December 20th, 2022|

Dempsey K, Saw R, Bartula I, Lo S, Lawn C, Pennington T, Spillane A, Boyle F, Dong S, Dieng M, Milne D, Seaman L, Saks D, Lai-Kwon J, Thompson JR, Morton R. BMJ Open. 2022 Dec 20;12(12):e066852. doi: 10.1136/bmjopen-2022-066852. PMID: 36600423; PMCID: PMC9772660.

 

|

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.

2023-01-21T22:32:20+11:00December 8th, 2022|

Rohaan MW, Borch TH, van den Berg JH, Met Ö, Kessels R, Geukes Foppen MH, Stoltenborg Granhøj J, Nuijen B, Nijenhuis C, Jedema I, van Zon M, Scheij S, Beijnen JH, Hansen M, Voermans C, Noringriis IM, Monberg TJ, Holmstroem RB, Wever LDV, van Dijk M, Grijpink-Ongering LG, Valkenet LHM, Torres Acosta A, Karger M, Borgers JSW, Ten Ham RMT, Retèl VP, van Harten WH, Lalezari F, van Tinteren H, van der Veldt AAM, Hospers GAP, Stevense-den Boer MAM, Suijkerbuijk KPM, Aarts MJB, Piersma D, van den Eertwegh AJM, de Groot JB, Vreugdenhil G, Kapiteijn E, Boers-Sonderen MJ, Fiets WE, van den Berkmortel FWPJ, Ellebaek E, Hölmich LR, van Akkooi ACJ, van Houdt WJ, Wouters MWJM, van Thienen JV, Blank CU, Meerveld-Eggink A, Klobuch S, Wilgenhof S, Schumacher TN, Donia M, Svane IM, Haanen JBAG. N Engl J Med. 2022 Dec 8;387(23):2113-2125. doi: 10.1056/NEJMoa2210233. PMID: 36477031.

|

Clinical features associated with outcomes and biomarker analysis of dabrafenib plus trametinib treatment in patients with BRAF-mutant melanoma brain metastases.

2023-01-21T22:57:07+11:00December 7th, 2022|

Wilmott JS, Tawbi H, Engh JA, Amankulor NM, Shivalingam B, Banerjee H, Vergara IA, Lee H, Johansson PA, Ferguson PM, Saiag P, Robert C, Grob JJ, Butterfield LH, Scolyer RA, Kirkwood JM, Long GV, Davies MA. Clin Cancer Res. 2022 Dec 7:CCR-22-2581. doi: 10.1158/1078-0432.CCR-22-2581. Epub ahead of print. PMID: 36477181.

|

BRAF inhibitor cessation prior to disease progression in metastatic melanoma: long term outcomes.

2022-11-20T14:37:39+11:00November 9th, 2022|

J. Lee, T. Ahmed, A. Maurichi, L. Di Guardo, A.M. Stagno, L. Warburton, A. Taylor, E. Livingstone, S. Rehman, A. Khattak, K. Kahler, V. Vanella, V. Atkinson, M. Millward, D. Schadendorf, D.B. Johnson, P.A. Ascierto, A. Hauschild, S.N. Lo, G.V. Long, A.M. Menzies, M.S. Carlino. European Journal of Cancer, 2022, ISSN 0959-8049, https://doi.org/10.1016/j.ejca.2022.11.009.

|

Combination of the STING Agonist MIW815 and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-label, Multicenter, Phase Ib Study.

2022-11-20T14:01:27+11:00October 25th, 2022|

Meric-Bernstam F, Sweis RF, Kasper S, Hamid O, Bhatia S, Dummer R, Stradella A, Long GV, Spreafico A, Shimizu T, Steeghs N, Luke JJ, McWhirter SM, Müller T, Nair N, Lewis N, Chen X, Bean A, Kattenhorn L, Pelletier M, Sandhu S. Clin Cancer Res. 2022 Oct 25:CCR-22-2235. doi: 10.1158/1078-0432.CCR-22-2235. Epub ahead of print. PMID: 36282874.

|

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.

2022-11-20T09:47:33+11:00October 18th, 2022|

Long GV, Luke JJ, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob J-J, de Galitiis F, Schadendorf D, Carlino MS, Mohr P, Dummer R, Gershenwald JE, Yoon CH, Wu XL, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Ascierto PA.  The Lancet Oncology, (Oct 18 2022)

|

Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study.

2022-11-20T13:34:01+11:00October 7th, 2022|

Serra-Bellver P, Versluis JM, Oberoi HK, Zhou C, Slattery TD, Khan Y, Patrinely JR, Pires da Silva I, Martínez-Vila C, Cook N, Graham DM, Carlino MS, Menzies AM, Arance AM, Johnson DB, Long GV, Pickering L, Larkin JMG, Blank CU, Lorigan P. Eur J Cancer. 2022 Oct 7;176:121-132. doi: 10.1016/j.ejca.2022.09.004. Epub ahead of print. PMID: 36215945.

 

|

Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

2022-11-20T09:27:24+11:00October 6th, 2022|

Blankenstein SA, Bonenkamp JJ, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Blokx WAM, Boers-Sonderen MJ, van den Eertwegh AJM, Franken MG, de Groot JWB, Haanen JBAG, Hospers GAP, Kapiteijn EW, van Not OJ, Piersma D, van Rijn RS, Suijkerbuijk KPM, van der Veldt AAM, Vreugdenhil G, Westgeest HM, Wouters MWJM, van Akkooi ACJ. Ann Surg Oncol. 2022 Oct 6. doi: 10.1245/s10434-022-12600-2. Epub ahead of print. PMID: 36203067.

|

Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study.

2022-11-19T22:44:45+11:00October 3rd, 2022|

Muhammad A. Khattak, Jason J. Luke, Georgina V. Long, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Caroline Robert, Jean-Jacques Grob, Luis de la Cruz Merino, Michele Del Vecchio, Francesco Spagnolo, Jacek Mackiewicz, Vanna Chiarion-Sileni, Matteo S. Carlino, Peter Mohr, Federica De Galitiis, Merrick I. Ross, Zeynep Eroglu, Ke Chen, Ruixuan Jiang, Mizuho Fukunaga-Kalabis, Clemens Krepler, Alexander M.M. Eggermont, John M. Kirkwood. European Journal of Cancer, 2022, ISSN 0959-8049

|

Obesity is associated with altered tumor metabolism in metastatic melanoma.

2022-11-19T22:24:52+11:00September 27th, 2022|

Hahn AW, Menk AV, Rivadeneira DB, Augustin RC, Xu M, Li J, Wu X, Mishra AK, Gide TN, Quek C, Zang Y, Spencer CN, Menzies AM, Daniel CR, Hudgens CW, Nowicki T, Haydu LE, Khan MAW, Gopalakrishnan V, Burton EM, Malke J, Simon JM, Bernatchez C, Putluri N, Woodman SE, Gopal Y N V, Guerrieri R, Fischer GM, Wang J, Wani KM, Thompson JF, Lee JE, Hwu P, Ajami N, Gershenwald JE, Long GV, Scolyer RA, Tetzlaff MT, Lazar AJ, Schadendorf D, Wargo JA, Kirkwood JM, DeBerardinis RJ, Liang H, Futreal A, Zhang J, Wilmott JS, Peng W, Davies MA, Delgoffe GM, Najjar YG, McQuade JL. Clin Cancer Res. 2022 Sep 27:CCR-22-2661. doi: 10.1158/1078-0432.CCR-22-2661. Epub ahead of print. PMID: 36166093.

|

Hypoxia controls the glycome signature and galectin-8 – ligand axis to promote pro-tumorigenic properties of metastatic melanoma.

2022-11-19T22:31:02+11:00September 26th, 2022|

Chakraborty A, Perez M, Carroll JD, Antonopoulos A, Dell A, Ortega L, Mohammed NBB, Wells M, Staudinger C, Griswold A, Chandler KB, Marrero C, Jimenez R, Tani Y, Wilmott JS, Thompson JF, Wang W, Sackstein R, Scolyer RA, Murphy GF, Haslam SM, Dimitroff CJ. J Invest Dermatol. 2022 Sep 26:S0022-202X(22)01931-5. doi: 10.1016/j.jid.2022.07.033. Epub ahead of print. PMID: 36174713.

|

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).

2022-11-19T22:17:24+11:00September 26th, 2022|

Weber JS, Schadendorf D, Del Vecchio M, Larkin J, Atkinson V, Schenker M, Pigozzo J, Gogas H, Dalle S, Meyer N, Ascierto PA, Sandhu S, Eigentler T, Gutzmer R, Hassel JC, Robert C, Carlino MS, Di Giacomo AM, Butler MO, Muñoz-Couselo E, Brown MP, Rutkowski P, Haydon A, Grob JJ, Schachter J, Queirolo P, de la Cruz-Merino L, van der Westhuizen A, Menzies AM, Re S, Bas T, de Pril V, Braverman J, Tenney DJ, Tang H, Long GV. J Clin Oncol. 2022 Sep 26:JCO2200533. doi: 10.1200/JCO.22.00533. Epub ahead of print. PMID: 36162037.

|

Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series.

2022-11-19T22:01:59+11:00September 23rd, 2022|

Smith JL, Menzies AM, Cohen JV, Mut-Lloret M, Ozgun A, Spain L, Park J, Quach HT, Pallan L, McQuade J, Feng S, Sandhu S, Atkinson V, Tsai K, Long GV, Larkin J, Eroglu Z, Johnson DB, Sullivan R, Herkes GK, Henderson A, Carlino MS. Melanoma Res. 2022 Sep 23. doi: 10.1097/CMR.0000000000000825. Epub ahead of print. PMID: 36164923.

|

Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study.

2022-11-19T22:37:15+11:00September 22nd, 2022|

Müller-Jensen L, Zierold S, Versluis JM, Boehmerle W, Huehnchen P, Endres M, Mohr R, Compter A, Blank CU, Hagenacker T, Meier F, Reinhardt L, Gesierich A, Salzmann M, Hassel JC, Ugurel S, Zimmer L, Banks P, Spain L, Soon JA, Enokida T, Tahara M, Kähler KC, Seggewiss-Bernhardt R, Harvey C, Long GV, Schöberl F, von Baumgarten L, Hundsberger T, Schlaak M, French LE, Knauss S, Heinzerling LM. CEur J Cancer. 2022 Sep 22;175:224-235. doi: 10.1016/j.ejca.2022.08.009. Epub ahead of print. PMID: 36155116.

 

|

Comparative genomics provides etiological and biological insights into melanoma subtypes

2022-10-09T21:35:02+11:00September 13th, 2022|

Newell F, Johansson PA, Wilmott JS, Nones K, Lakis V, Pritchard AL, Lo SN, Rawson RV, Kazakoff SH, Colebatch AJ, Koufariotis LT, Ferguson PM, Wood S, Leonard C, Law MH, Brooks KM, Broit N, Palmer JM, Couts KL, Vergara IA, Long GV, Barbour AP, Nieweg OE, Shivalingam B, Robinson WA, Stretch JR, Spillane AJ, Saw RPM, Shannon KF, Thompson JF, Mann GJ, Pearson JV, Scolyer RA, Waddell N, Hayward NK. Cancer Discov. 2022 Sep 13:CD-22-0603. doi: 10.1158/2159-8290.CD-22-0603. Epub ahead of print. PMID: 36098958.

|

Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma.

2022-10-23T20:07:40+11:00September 10th, 2022|

Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Boers-Sonderen M, Di Giacomo AM, van den Eertwegh AJM, Grob J-J, Gutzner R, Jamal R, van Akkooi ACJ, Lorigan P, Grebennik D, Krepler C, Marreaud S, Suciu S, Robert C.  NEJM Evidence. 2022 Sep 10. doi: 10.1056/EVIDoa2200214. Epub ahead of print.

|

In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response.

2022-10-23T19:14:26+11:00September 9th, 2022|

Sahu A, Kose K, Kraehenbuehl L, Byers C, Holland A, Tembo T, Santella A, Alfonso A, Li M, Cordova M, Gill M, Fox C, Gonzalez S, Kumar P, Wang AW, Kurtansky N, Chandrani P, Yin S, Mehta P, Navarrete-Dechent C, Peterson G, King K, Dusza S, Yang N, Liu S, Phillips W, Guitera P, Rossi A, Halpern A, Deng L, Pulitzer M, Marghoob A, Chen CJ, Merghoub T, Rajadhyaksha M. Nat Commun. 2022 Sep 9;13(1):5312. doi: 10.1038/s41467-022-32738-7. PMID: 36085288; PMCID: PMC9463451.

|

Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome.

2022-10-23T19:53:17+11:00September 1st, 2022|

Simpson RC, Shanahan ER, Batten M, Reijers ILM, Read M, Silva IP, Versluis JM, Ribero R, Angelatos AS, Tan J, Adhikari C, Menzies AM, Saw RPM, Gonzalez M, Shannon KF, Spillane AJ, Velickovic R, Lazar AJ, Damania AV, Mishra AK, Chelvanambi M, Banerjee A, Ajami NJ, Wargo JA, Macia L, Holmes AJ, Wilmott JS, Blank CU, Scolyer RA, Long GV. Nat Med 2022 Sep 22. doi: 10.1038/s41591-022-01965-2. Epub ahead of print.

|

Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline – Update 2022.

2022-11-20T10:26:50+11:00August 1st, 2022|

Gauci ML, Aristei C, Becker JC, Blom A, Bataille V, Dreno B, Del Marmol V, Forsea AM, Fargnoli MC, Grob JJ, Gomes F, Hauschild A, Hoeller C, Harwood C, Kelleners-Smeets N, Kaufmann R, Lallas A, Malvehy J, Moreno-Ramirez D, Peris K, Pellacani G, Saiag P, Stratigos AJ, Vieira R, Zalaudek I, van Akkooi ACJ, Lorigan P, Garbe C, Lebbé C; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer. 2022 Aug;171:203-231. doi: 10.1016/j.ejca.2022.03.043. Epub 2022 Jun 19. PMID: 35732101.

|

Impact of Next-generation Sequencing on Interobserver Agreement and Diagnosis of Spitzoid Neoplasms.

2022-07-23T17:39:25+10:00December 1st, 2021|

Benton S, Zhao J, Zhang B, Bahrami A, Barnhill RL, Busam K, Cerroni L, Cook MG, de la Fouchardière A, Elder DE, Johansson I, Landman G, Lazar A, LeBoit P, Lowe L, Massi D, Duncan LM, Messina J, Mihic-Probst D, Mihm MC Jr, Piepkorn MW, Schmidt B, Scolyer RA, Shea CR, Tetzlaff MT, Tron VA, Xu X, Yeh I, Yun SJ, Zembowicz A, Gerami P. Am J Surg Pathol. 2021 Dec 1;45(12):1597-1605

|

Assessing the Potential for Patient-led Surveillance After Treatment of Localized Melanoma (MEL-SELF): A Pilot Randomized Clinical Trial.

2022-07-23T17:22:11+10:00November 24th, 2021|

Ackermann DM, Dieng M, Medcalf E, Jenkins MC, van Kemenade CH, Janda M, Turner RM, Cust AE, Morton RL, Irwig L, Guitera P, Soyer HP, Mar V, Hersch JK, Low D, Low C, Saw RPM, Scolyer RA, Drabarek D, Espinoza D, Azzi A, Lilleyman AM, Smit AK, Murchie P, Thompson JF, Bell KJL. JAMA Dermatol. (Epub 24 Nov 2021)

|

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.

2022-07-23T17:15:22+10:00November 24th, 2021|

Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Butler MO, Hill A, Márquez-Rodas I, Haanen JBAG, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bas T, Ritchings C, Larkin J, Hodi FS. J Clin Oncol. (Epub 24 Nov 2021)

|

Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition – A Descriptive Observational Retrospective Multicenter Analysis.

2022-07-23T16:44:16+10:00October 21st, 2021|

Zaremba A, Kramer R, De Temple V, Bertram S, Salzmann M, Gesierich A, Reinhardt L, Baroudjian B, Sachse MM, Mechtersheimer G, Johnson DB, Weppler AM, Spain L, Loquai C, Dudda M, Pföhler C, Hepner A, Long GV, Menzies AM, Carlino MS, Lebbé C, Enokida T, Tahara M, Bröckelmann PJ, Eigentler T, Kähler KC, Gutzmer R, Berking C, Ugurel S, Stadtler N, Sucker A, Becker JC, Livingstone E, Meier F, Hassel JC, Schadendorf D, Hanoun M, Heinzerling L, Zimmer L. Front Oncol. (21 Oct 2021)

|

Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma.

2022-07-23T20:29:32+10:00October 15th, 2021|

Peri A, Greenstein E, Alon M, Pai JA, Dingjan T, Reich-Zeliger S, Barnea E, Barbolin C, Levy R, Arnedo-Pac C, Kalaora S, Dassa B, Feldmesser E, Shang P, Greenberg P, Levin Y, Benedek G, Levesque MP, Adams DJ, Lotem M, Wilmott JS, Scolyer RA, Jönsson GB, Admon A, Rosenberg SA, Cohen CJ, Niv MY, Lopez-Bigas N, Satpathy AT, Friedman N, Samuels Y. J Clin Invest. 2021 Oct 15;131(20):e129466.

|

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES).

2022-07-23T20:20:49+10:00October 8th, 2021|

Lau PKH, Feran B, Smith L, Lasocki A, Molania R, Smith K, Weppler A, Angel C, Kee D, Bhave P, Lee B, Young RJ, Iravani A, Yeang HA, Vergara IA, Kok D, Drummond K, Neeson PJ, Sheppard KE, Papenfuss T, Solomon BJ, Sandhu S, McArthur GA. J Immunother Cancer. (Epub 8 Oct 2021)

|

Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts.

2022-07-23T19:23:39+10:00September 8th, 2021|

Haggenmüller S, Maron RC, Hekler A, Utikal JS, Barata C, Barnhill RL, Beltraminelli H, Berking C, Betz-Stablein B, Blum A, Braun SA, Carr R, Combalia M, Fernandez-Figueras MT, Ferrara G, Fraitag S, French LE, Gellrich FF, Ghoreschi K, Goebeler M, Guitera P, Haenssle HA, Haferkamp S, Heinzerling L, Heppt MV, Hilke FJ, Hobelsberger S, Krahl D, Kutzner H, Lallas A, Liopyris K, Llamas-Velasco M, Malvehy J, Meier F, Müller CSL, Navarini AA, Navarrete-Dechent C, Perasole A, Poch G, Podlipnik S, Requena L, Rotemberg VM, Saggini A, Sangueza OP, Santonja C, Schadendorf D, Schilling B, Schlaak M, Schlager JG, Sergon M, Sondermann W, Soyer HP, Starz H, Stolz W, Vale E, Weyers W, Zink A, Krieghoff-Henning E, Kather JN, von Kalle C, Lipka DB, Fröhling S, Hauschild A, Kittler H, Brinker TJ. Eur J Cancer. (Epub 8 Sept 2021)

|

Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognition.

2022-07-23T19:11:07+10:00August 25th, 2021|

Grob JJ, Guminski A, Malvehy J, Basset-Seguin N, Bertrand B, Fernandez-Penas P, Kaufmann R, Zalaudek I, Gaudy-Marqueste C, Fargnoli MC, Tagliaferri L, Fertil B, Del Marmol V, Stratigos A, Garbe C, Peris K. J Eur Acad Dermatol Venereol. (Epub 25 Aug 2021)

|

Early use of high-dose-glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy

2022-07-23T18:42:02+10:00August 10th, 2021|

Bai X, Hu J, Betof Warner A, Quach HT, Cann CG, Zhang MZ, Si L, Tang B, Cui C, Yang X, Wei X, Pallan L, Harvey C, Manos MP, Ouyang O, Kim MS, Kasumova G, Cohen JV, Lawrence DP, Freedman C, Fadden RM, Rubin KM, Sharova T, Frederick DT, Flaherty KT, Rahma OE, Long GV, Menzies AM, Guo J, Shoushtari AN, Johnson DB, Sullivan RJ, Boland GM. Clin Cancer Res. (Epub 10 Aug 2021)

|

Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib

2022-07-23T22:00:01+10:00June 9th, 2021|

Brase JC, Walter RFH, Savchenko A, Gusenleitner D, Garrett J, Schimming TT, Váraljai R, Castelletti D, Kim JY, Dakappagari NK, Schultz K, Robert C, Long GV, Nathan PD, Ribas A, Flaherty KT, Karaszewska B, Schachter J, Sucker A, Schmid KW, Zimmer L, Livingstone E, Gasal E, Schadendorf D, Roesch A. Clin Cancer Res. (Epub 9 June 2021)

|

Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial

2022-07-25T21:12:03+10:00April 30th, 2021|

Jason J Luke, Prof Piotr Rutkowski, Paola Queirolo, Michele Del Vecchio, Prof Jacek Mackiewicz, Vanna Chiarion-Sileni, Luis de la Cruz Merino, Prof Muhammad A Khattak, Prof Dirk Schadendorf, Prof Georgina V Long, Paolo A Ascierto, Mario Mandala, Federica De Galitiis, Andrew Haydon, Reinhard Dummer, Prof Jean-Jacques Grob, Caroline Robert, Matteo S Carlino, Peter Mohr, Andrew Poklepovic, Prof Vernon K Sondak, Prof Richard A Scolyer, John M Kirkwood, Ke Chen, Scott J Diede, Sama Ahsan, Nageatte Ibrahim, Prof Alexander M M. Lancet. (30 Apr 2022)

|

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

2022-06-09T10:58:09+10:00February 9th, 2021|

Alexander M. Menzies, Rodabe N. Amaria, Elisa A. Rozeman, Alexander C. Huang, Michael T. Tetzlaff, Bart A. van de Wiel, Serigne Lo, Ahmad A. Tarhini, Elizabeth M. Burton, Thomas E. Pennington, Robyn P. M. Saw, Xiaowei Xu, Giorgos C. Karakousis, Paolo A. Ascierto, Andrew J. Spillane, Alexander C. J. van Akkooi, Michael A. Davies, Tara C. Mitchell, Hussein A. Tawbi, Richard A. Scolyer, Jennifer A. Wargo, Christian U. Blank & Georgina V. Long.  Nat Med (2021).

|

Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.

2022-07-25T22:17:12+10:00February 1st, 2021|

Bhave P, Pallan L, Long GV, Menzies AM, Atkinson V, Cohen JV, Sullivan RJ, Chiarion-Sileni V, Nyakas M, Kahler K, Hauschild A, Plummer R, Trojaniello C, Ascierto PA, Zimmer L, Schadendorf D, Allayous C, Lebbe C, Maurichi A, Santinami M, Roy S, Robert C, Lesimple T, Patel S, Versluis JM, Blank CU, Khattak A, Van der Westhuizen A, Carlino MS, Shackleton M, Haydon A. Br J Cancer. 2021 Feb;124(3):574-580.

|

Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy

2022-11-09T10:00:00+11:00February 11th, 2019|

Tuba N. Gide, Camelia Quek, Alexander M. Menzies, Annie T. Tasker, Ping Shang, Jeff Holst, Jason Madore, Su Yin Lim, Rebecca Velickovic, Matthew Wongchenko, Yibing Yan, Serigne Lo, Matteo S. Carlino, Alexander Guminski, Robyn P.M. Saw, Angel Pang, Helen M. McGuire, Umaimainthan Palendira, John F. Thompson, Helen Rizos, Ines Pires da Silva,
Marcel Batten, Richard A. Scolyer, Georgina V. Long, James S. Wilmott. Cancer Cell Volume 35, Issue 2, P238-255.E6

|

For earlier research papers, prior to 2021, please email digital@melanoma.org.au.  

Go to Top